RM Primary Logo - Humble.png
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
March 28, 2024 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Dyadic Logo Current.jpg
Dyadic Reports 2023 Full Year Results and Recent Company Progress
March 28, 2024 16:00 ET | Dyadic International, Inc.
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
AVEO_LG Chem_Logo(Hi-Resolution).jpg
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
March 28, 2024 15:22 ET | AVEO Pharmaceuticals, Inc.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned...
RNAZ White background cropped.jpg
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024 08:30 ET | TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Dyadic Logo Current.jpg
Dyadic Announces Change in Board and Management Leadership Roles
March 28, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
AIMLogo.jpg
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
March 28, 2024 08:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM...
Tevogen Logo Notified.png
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
March 28, 2024 08:05 ET | Tevogen Bio Inc
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
purple-logo2020.png
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
March 28, 2024 07:00 ET | Purple Biotech Ltd.
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...
Tevogen Logo Notified.png
Tevogen Bio Announces Series A-1 Preferred Stock Investment
March 27, 2024 09:20 ET | Tevogen Bio Inc
The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
Immuneering-logo (1).png
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024 08:00 ET | Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations